The following list of cancer immunotherapies are available for licensing under U.S. Patent Publication No.: 20220298491.

Pluripotent Stem Cell Derived Dendritic Cells and Engineered Dendritic Cells for Cancer Immunotherapy

Abstract
Disclosed are populations of dendritic cells generated from stem cells capable of inducing immunity towards cancer. In one embodiment said dendritic cells are generated from allogeneic inducible pluripotent stem cells, for some uses, said pluripotent stem cells are genetically engineered/edited to induce cancer specific immunity and/or resist immunosuppressive effect of tumor derived microenvironment. In one embodiment pluripotent stem cells are transfected with cancer stem cell antigens such as BORIS and/or NR2F6.






Acute nonlymphocytic leukemia is a fast-growing cancer in which too many myeloblasts (a type of immature white blood cell) are found in the bone marrow and blood. Acute nonlymphocytic leukemia usually gets worse quickly if it is not treated. It can spread outside the blood to other parts of the body, including the lymph nodes, spleen, liver, central nervous system (brain and spinal cord), skin, gums, and testicles. Acute nonlymphocytic leukemia is most common in older adults. Also called acute myelogenous leukemia, acute myeloid leukemia, AML, and ANLL.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). CLL is a cancer of the blood and bone marrow that usually gets worse slowly.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Acute granulocytic leukemia is a cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Chronic granulocytic leukemia typically affects older adults. It’s caused by a chromosome mutation that occurs spontaneously. Doctors aren’t sure what causes the mutation.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Acute promyelocytic leukemia is a subtype of acute myeloid leukemia, a cancer of the white blood cells. In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Adult t-cell leukemia (ATL) is a highly aggressive mature T-cell neoplasm associated with human T-cell lymphotropic virus type 1 (HTLV-1) infection, which affects around 10 million people in the world.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Aleukemic leukemia is the primary extramedullary cutaneous infiltration of neoplastic leukemic cells that occasionally precede systemic leukemia diagnosis. This study aimed to investigate the clinical characteristics, management, and outcomes of ALC patients to expand our knowledge of this rare entity.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Aleukocythemic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). CLL is a cancer of the blood and bone marrow that usually gets worse slowly.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Basophilic leukemia is an extremely rare type of leukemia and very little information related to the prognosis and survival of this rare variant is available.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Blast cell leukemia is abnormal immature white blood cells (called blasts) multiply uncontrollably, filling up the bone marrow, and preventing production of other cells important for survival, namely red blood cells and platelets. This leads to infections, anemia and abnormal bleeding.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Chronic myelocytic leukemia typically affects older adults. It’s caused by a chromosome mutation that occurs spontaneously. Doctors aren’t sure what causes the mutation.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Leukemia cutis is the infiltration of neoplastic leukocytes or their precursors into the epidermis, the dermis, or the subcutis, resulting in clinically identifiable cutaneous lesions. The dermatologist is often instrumental in the diagnosis of leukemia cutis.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Embryonal leukemia are uncontrolled growths of cells in the brain. The growths involve cells that are left over from fetal development, called embryonal cells.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Eosinophilic leukemia is a blood cancer that causes an excess of eosinophils in the body.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Gross’ leukemia is a cancer of the blood, characterized by the rapid growth of abnormal blood cells. This uncontrolled growth takes place in your bone marrow.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Rieder cell leukemia is an abnormal form of lymphocyte with a greatly indented nucleus, usually observed in certain examples of chronic lymphocytic leukemia.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Schilling’s leukemia proposes that all monocytic leukemias were derived from the reticuloendothelial system

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Stem cell leukemia occurs most often in adults older than 55, but it is also the most common cancer in children younger than 15.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Subleukemic leukemia, also known as leukemia subleukemic and aleukemic leukemia cutis, is a rare, cancerous blood disease characterized by the presence of abnormal or atypical white blood cells in the peripheral blood while the total white blood cell count is within the normal range.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Undifferentiated cell leukemia is a rare acute leukemia of ambiguous lineage characterized by clonal proliferation of primitive hematopoietic cells, primarily in the bone marrow and blood, lacking lineage-specific markers and detectable genotypic alterations.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Hairy-cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a subtype of chronic lymphocytic leukemia.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Hemoblastic leukemia is a subtype of acute myeloid leukemia (AML).

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Hemocytoblastic leukemia is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Histiocytic leukemia is an extremely rare malignant neoplasm. Tumors can occur over a wide range of ages (median age: 46 years), and is more common in males.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Acute monocytic leukemia is a type of acute myeloid leukemia. In AML-M5 >80% of the leukemic cells are of monocytic lineage.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Leukopenic leukemia is when a person has a low white blood cell count. The most common type of leukopenia is neutropenia, which refers to low levels of neutrophils.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lymphatic leukemia are a group of leukemias affecting circulating lymphocytes, a type of white blood cell. The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lymphoblastic leukemia s a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Leukemia may affect red blood cells, white blood cells, and platelets. Previous chemotherapy and exposure to radiation may increase the risk of developing ALL.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). CLL is a cancer of the blood and bone marrow that usually gets worse slowly.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lymphogenous leukemia is a type of cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The word “acute” in acute lymphocytic leukemia comes from the fact that the disease progresses rapidly and creates immature blood cells, rather than mature ones.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lymphoid leukemias are a group of leukemias affecting circulating lymphocytes, a type of white blood cell. The lymphocytic leukemias are closely related to lymphomas of the lymphocytes, to the point that some of them are unitary disease entities that can be called by either name.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Lymphosarcoma cell leukemia is an atypical, large lymphocyte with coarsely reticulated nuclear chromatin and a single prominent nucleolus. The maturity of these cells correlates with the chronicity or acuteness of the leukemic process.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Mast cell leukemia is the leukemic form of SM with at least 20% mostly immature mast cells on bone marrow aspirate.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Megakaryocyticleukemia is a rare malignancy affecting megakaryocytes, platelet-producing cells that reside in the bone marrow.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Micromyeloblastic leukemia is characterized by the clonal proliferation of undifferentiated myeloid precursors, known as blasts, within the bone marrow compartment.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Monocytic leukemia is a type of myeloid leukemia characterized by a dominance of monocytes in the marrow.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Myeloblastic leukemia is a type of cancer that starts in the blood-forming cells of the bone marrow.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Myelocytic leukemia is a cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Myeloid granulocytic leukemia is blood cancer that starts in the blood-forming myeloid cells or stem cells in your bone marrow.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Myelomonocytic leukemia is a type of leukemia, which are cancers of the blood-forming cells of the bone marrow. In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Naegeli leukemia, unknown factors may cause alterations in the type of cell released from the marrow.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Plasma cell leukemia is defined by the presence of 5% or more circulating plasma cells in peripheral blood smears.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Plasmacytic leukemia is a rare, yet aggressive form of multiple myeloma (MM) characterized by plasma cells circulating in the peripheral blood that can be detected on conventional peripheral blood smear examination.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%

Promyelocytic leukemi is a subtype of acute myeloid leukemia, a cancer of the white blood cells. In APL, there is an abnormal accumulation of immature granulocytes called promyelocytes.

Upfront Fee Annual Minimum Royalty Phase 1 IND Phase 2 IND Phase 3 IND BLA Royalty
$50,000 $10,000 $100,000 $250,000 $500,000 $1,000,000 6%